Ruxolitinib is a new drug that inhibits Janus kinase (JAK) enzymes. It is indicated for the treatment of myelofibrosis and polycythemia vera. The document discusses the drug's composition, dosing regimen, safety information, and clinical pharmacology. It recommends starting doses based on platelet count and monitoring blood counts regularly. Adverse effects can include infections, bleeding, anemia, and lipid abnormalities. Dose reductions may be needed in renal or hepatic impairment.
ASSESSMENT OF CKD PATIENT BEFORE INITIATION OF HEMODIALYSIS.pptxGita Bipin Chandra
This document summarizes the assessment and management of chronic kidney disease (CKD) patients. It discusses predicting when patients will require dialysis based on declining glomerular filtration rate. It also compares peritoneal dialysis versus hemodialysis. Key aspects of CKD patient assessment and management are outlined, including volume overload, hyperkalemia, anemia, CKD-mineral and bone disorder, nutrition, vaccination, and vascular access planning.
CPG: Prevention and Treatment of Venous Thromboembolism (VTE)Khairunnisa Zamri
This document provides guidelines for the prevention and treatment of venous thromboembolism (VTE). It defines VTE as deep vein thrombosis and pulmonary embolism. It discusses the epidemiology, causes, risk factors, pathophysiology and various methods for prophylaxis and treatment of VTE, including pharmacological agents such as low molecular weight heparins, fondaparinux, vitamin K antagonists, and new oral anticoagulants. It also covers topics such as risk assessment, timing of prophylaxis, duration of treatment and switching between different anticoagulation agents.
This document summarizes the clinical pharmacology of oral anticoagulants including warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban in patients with kidney disease. It discusses the pharmacokinetics, dosing adjustments, and safety considerations for each drug in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). While newer oral anticoagulants have been shown to be more effective than warfarin in the general population, their use in patients with CKD and ESKD remains limited due to a lack of clinical trial data in these groups. Warfarin remains the most widely used oral anticoagulant for
This document summarizes the clinical pharmacology of oral anticoagulants including warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban in patients with kidney disease. It finds that while these drugs require dosage adjustment for patients with reduced kidney function, warfarin remains the most widely used option due to lack of comparative data for the newer anticoagulants in patients with severe kidney disease. The pharmacokinetics and pharmacodynamics of each drug are reviewed in detail, along with considerations for reversal agents and monitoring in patients with kidney impairment. The conclusion recommends that apixaban may be an alternative to warfarin if time in the therapeutic INR range is low
Hepatic Considerations In Oral Surgery .pptxSudiptaBera9
This document provides an overview of considerations for oral surgery in patients with liver disease. It discusses the functional role of the liver and risks associated with dental care for patients with liver disease such as impaired hemostasis, drug interactions, and increased susceptibility to infection. It also covers preoperative evaluation including liver function tests and coagulation assessment. Guidelines are provided for preoperative management including vitamin K replacement, drug dosing adjustments based on liver function, and anesthesia considerations. Postoperative management focuses on hemostasis and infection control.
Cyclosporine is an immunosuppressant used for several transplant and autoimmune indications. It is administered orally or intravenously, with dosing adjustments not typically required for kidney or liver impairment but dose reductions potentially needed for severe liver impairment. Administration instructions vary based on the formulation and patient age. Labeled indications include preventing transplant rejection and treating severe plaque psoriasis, while it is also commonly used off-label for several other autoimmune and hematologic conditions.
R.M. is a 40-year-old male admitted with ascites, tense abdomen, vomiting, and jaundice. He has HCV, prior SBP, and esophageal varices. Diagnostic paracentesis found SBP. He is started on cefotaxime for SBP. The drug regimen has some issues: acetylcysteine and cefotriaxone are unnecessary. Albumin dosing is subtherapeutic. Advice is provided on addressing untreated conditions like anemia, managing medications like aldactone due to renal impairment, and discontinuing medical errors. Patient counseling covers diet, medications to avoid, and monitoring weight.
This document summarizes an audit of albuminuria management in diabetic patients. The audit aimed to evaluate current clinical practice and encourage adherence to guidelines. It reviewed 133 patients with abnormal or no albumin-to-creatinine ratio testing in 2017. Key recommendations include ensuring proper documentation, informing laboratories that urine samples are for albumin-creatinine ratio testing, educating providers on proteinuria guidelines, and conducting annual audits to assess adherence.
ASSESSMENT OF CKD PATIENT BEFORE INITIATION OF HEMODIALYSIS.pptxGita Bipin Chandra
This document summarizes the assessment and management of chronic kidney disease (CKD) patients. It discusses predicting when patients will require dialysis based on declining glomerular filtration rate. It also compares peritoneal dialysis versus hemodialysis. Key aspects of CKD patient assessment and management are outlined, including volume overload, hyperkalemia, anemia, CKD-mineral and bone disorder, nutrition, vaccination, and vascular access planning.
CPG: Prevention and Treatment of Venous Thromboembolism (VTE)Khairunnisa Zamri
This document provides guidelines for the prevention and treatment of venous thromboembolism (VTE). It defines VTE as deep vein thrombosis and pulmonary embolism. It discusses the epidemiology, causes, risk factors, pathophysiology and various methods for prophylaxis and treatment of VTE, including pharmacological agents such as low molecular weight heparins, fondaparinux, vitamin K antagonists, and new oral anticoagulants. It also covers topics such as risk assessment, timing of prophylaxis, duration of treatment and switching between different anticoagulation agents.
This document summarizes the clinical pharmacology of oral anticoagulants including warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban in patients with kidney disease. It discusses the pharmacokinetics, dosing adjustments, and safety considerations for each drug in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). While newer oral anticoagulants have been shown to be more effective than warfarin in the general population, their use in patients with CKD and ESKD remains limited due to a lack of clinical trial data in these groups. Warfarin remains the most widely used oral anticoagulant for
This document summarizes the clinical pharmacology of oral anticoagulants including warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban in patients with kidney disease. It finds that while these drugs require dosage adjustment for patients with reduced kidney function, warfarin remains the most widely used option due to lack of comparative data for the newer anticoagulants in patients with severe kidney disease. The pharmacokinetics and pharmacodynamics of each drug are reviewed in detail, along with considerations for reversal agents and monitoring in patients with kidney impairment. The conclusion recommends that apixaban may be an alternative to warfarin if time in the therapeutic INR range is low
Hepatic Considerations In Oral Surgery .pptxSudiptaBera9
This document provides an overview of considerations for oral surgery in patients with liver disease. It discusses the functional role of the liver and risks associated with dental care for patients with liver disease such as impaired hemostasis, drug interactions, and increased susceptibility to infection. It also covers preoperative evaluation including liver function tests and coagulation assessment. Guidelines are provided for preoperative management including vitamin K replacement, drug dosing adjustments based on liver function, and anesthesia considerations. Postoperative management focuses on hemostasis and infection control.
Cyclosporine is an immunosuppressant used for several transplant and autoimmune indications. It is administered orally or intravenously, with dosing adjustments not typically required for kidney or liver impairment but dose reductions potentially needed for severe liver impairment. Administration instructions vary based on the formulation and patient age. Labeled indications include preventing transplant rejection and treating severe plaque psoriasis, while it is also commonly used off-label for several other autoimmune and hematologic conditions.
R.M. is a 40-year-old male admitted with ascites, tense abdomen, vomiting, and jaundice. He has HCV, prior SBP, and esophageal varices. Diagnostic paracentesis found SBP. He is started on cefotaxime for SBP. The drug regimen has some issues: acetylcysteine and cefotriaxone are unnecessary. Albumin dosing is subtherapeutic. Advice is provided on addressing untreated conditions like anemia, managing medications like aldactone due to renal impairment, and discontinuing medical errors. Patient counseling covers diet, medications to avoid, and monitoring weight.
This document summarizes an audit of albuminuria management in diabetic patients. The audit aimed to evaluate current clinical practice and encourage adherence to guidelines. It reviewed 133 patients with abnormal or no albumin-to-creatinine ratio testing in 2017. Key recommendations include ensuring proper documentation, informing laboratories that urine samples are for albumin-creatinine ratio testing, educating providers on proteinuria guidelines, and conducting annual audits to assess adherence.
A simple description of a less understood topic in Intensive Care Medicine. Aim to make understanding and management easy for the residents and prevention steps for all ICU workers.
Dosage regimen in renal failure ( Neha Mayekar).pptxSaishDalvi
This document discusses dosage adjustment in patients with renal failure. It notes that renal failure can impact drug absorption, distribution, metabolism and excretion. Two main methods are described for adjusting dosages - based on drug clearance or based on changes in elimination rate constant. The goal is to maintain therapeutic drug concentrations while accounting for changes like prolonged half-life. Formulas for estimating creatinine clearance, which indicates renal function, are also provided to help determine appropriate dosage adjustments for patients with impaired kidney function.
This document provides guidelines for screening, treating, and managing lupus nephritis (LN). It defines LN and its classification system. For classes I and II LN, treatment focuses on extrarenal symptoms. Classes III and IV are treated aggressively with glucocorticoids and immunosuppressants. Maintenance therapy includes azathioprine or mycophenolate mofetil with low-dose steroids. Relapse is treated with the initial regimen. The guidelines recommend treatments and monitoring for various LN classes and complications.
Dose Adjustment in renal and hepatic failurePallavi Kurra
This document discusses dosage adjustments for patients with renal or hepatic failure. It covers:
1) Causes, classification, and measurement of renal failure including glomerular filtration rate (GFR) and creatinine clearance. Dosage adjustments are recommended based on GFR for various drug classes.
2) Causes, classification, and liver function tests for hepatic failure. Considerations for dosage adjustments in patients with hepatic impairment include drug elimination pathways and protein binding.
3) Formulas for estimating creatinine clearance from serum creatinine levels, including the Cockcroft-Gault and modification of diet in renal disease (MDRD) methods.
This document provides guidance statements on the diagnosis, evaluation and management of ascites, spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome (HRS) for patients with cirrhosis. It recommends moderate sodium restriction and diuretic therapy as first-line treatment for ascites. Large volume paracentesis is recommended for severe ascites. Albumin infusion and antibiotics are recommended for SBP treatment and prophylaxis. Vasoconstrictor drugs in combination with albumin are the treatment of choice for HRS, with terlipressin as the preferred drug.
Luspatercept is a first-in-class erythroid maturation agent that targets TGF-β ligands to block aberrant Smad2/3 signaling and augment late-stage erythropoiesis. It is indicated for treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusions. The BELIEVE trial met its primary endpoint, showing luspatercept significantly reduced transfusion burden in patients with beta-thalassemia. Additional trials show luspatercept was effective in reducing transfusion requirements in lower-risk myelodysplastic syndromes with ring sideroblasts and was generally well-tolerated. Luspatercept has the potential to be
This document summarizes current treatment guidelines for lupus nephritis. It defines lupus nephritis based on ACR criteria and recommends an early renal biopsy. For initial treatment of proliferative lupus nephritis (classes III/IV), guidelines differ on whether cyclophosphamide or mycophenolate mofetil is preferred. Maintenance therapy with mycophenolate mofetil or azathioprine with low-dose steroids is recommended, with mycophenolate mofetil showing better outcomes. Immunosuppression should be continued for at least one year after complete remission is achieved.
1) The ATTIRE trial investigated whether daily albumin infusions would reduce infections and organ dysfunction in hospitalized patients with cirrhosis compared to standard care. 2) Over 700 patients with cirrhosis were randomly assigned to either daily albumin infusions or standard care without explicit albumin therapy for up to 14 days. 3) The trial found no benefit of albumin therapy over standard care on the composite primary outcome of infections, organ dysfunction and mortality.
Venous thromboembolisms often result from Virchow's triad of altered blood flow, endothelial injury, and hypercoagulability. Lovenox is commonly used to treat and prevent VTEs as it inhibits coagulation factors Xa and IIa. It has high bioavailability, is metabolized in the liver, and has a half-life of 4.5-7 hours. Bleeding is the most common side effect. A multidisciplinary approach including hematology consultation is recommended for oncology patients at high risk of VTEs, as Lovenox is more effective than warfarin for this population.
Cirrhosis is irreversible scarring of the liver caused by various chronic liver injuries and diseases. It is a major global health issue and the 13th leading cause of death worldwide. The major causes of cirrhosis are hepatitis B, hepatitis C, alcoholism, and non-alcoholic fatty liver disease. Patients with cirrhosis have progressive liver damage and fibrosis that leads to complications including portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and liver cancer. Without treatment, survival is typically 10-13 years after diagnosis but can decrease to just 2 years once complications develop.
Optimization of Heart Failure Treatment ppt.pptxpradeepbansal34
The document discusses guidelines for treating heart failure with reduced ejection fraction (HFrEF). It recommends initiating all four foundational therapies - ACE inhibitors, ARBs, beta blockers, and mineralocorticoid receptor antagonists (MRA) - as early as possible without delay to maximize mortality benefits. The practical approach involves optimizing volume status with diuretics before starting renin-angiotensin system inhibitors (RASi). RASi are then up-titrated gradually followed by beta blockers and MRAs. Close monitoring is needed when using combinations of drugs to safely reach guideline directed medical therapy goals.
Discussion of the current medications of chronic hepatitis treatment in the Egyptian market as well as our protocol of management in the Viral Hepatitis Treatment Centers in Egypt. Discussion of the latest recommendations of AASLD/IDSA and EASL are presented
The document summarizes several drug approvals and updates from the FDA in August 2017. Mavyret was approved for treating HCV genotypes 1-6 without cirrhosis or with compensated cirrhosis. Carospir received approval as an oral suspension for heart failure, hypertension, and hepatic edema. Duzallo was approved as a combination of lesinurad and allopurinol for treating gout in patients not at target uric acid levels on allopurinol alone. Vabomere was approved for complicated UTIs caused by designated bacteria. Other notable approvals included Idhifa for AML, Besponsa for ALL, and Benznidazole for Chagas disease in pediatric patients.
This particular presentation of mine covers salient features of recent drug developed for treatment of dyslipidaemia particularly familial hypercholesterolemia. This presentation also covers recent modifications in treatment guidelines.
This document outlines the design of a randomized controlled trial testing the effects of empagliflozin versus placebo in patients with heart failure with preserved ejection fraction. Over 5,900 patients were enrolled and followed for a median of 26 months. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. Empagliflozin reduced the primary outcome compared to placebo and was generally well tolerated aside from higher rates of genital infections.
This document provides guidelines for perioperative care in elective colorectal surgery as part of an Enhanced Recovery After Surgery (ERAS) protocol. It makes recommendations for several preadmission items including preadmission counselling and education, preoperative optimization of medical conditions, prehabilitation, preoperative nutrition, management of anemia, and prevention of postoperative nausea and vomiting. The recommendations are based on reviews of the available evidence and are intended to reduce complications and facilitate early recovery after colorectal surgery.
This document provides an overview of anticoagulants including their mechanisms of action, indications, dosing, and monitoring. It discusses normal hemostasis and coagulation factors. Unfractionated heparin, low molecular weight heparins, and factor Xa inhibitors are described as parenteral anticoagulants. Oral anticoagulants reviewed include warfarin, rivaroxaban, apixaban, and dabigatran. The roles of clinical pharmacists in managing anticoagulation therapy are also mentioned.
This document discusses several deep fungal infections caused by dimorphic fungi, including blastomycosis, paracoccidioidomycosis, coccidioidomycosis, and histoplasmosis. It provides details on the causative agents, modes of transmission, clinical presentations, laboratory diagnosis including microscopy and culture, and treatment for each infection. The infections are acquired through inhalation of fungal spores from the soil and can affect the lungs, skin, and other organs. Laboratory diagnosis involves microscopy of specimens to identify fungal structures, culture, and serological tests. Antifungals such as amphotericin B and azoles are used as treatment.
Sudden Cardiac Death and Chronic Kidney DiseaseShodhan Patel
Sudden cardiac death is responsible for about one fourth of all cause mortality in dialysis patients. In chronic kidney disease, factors like left ventricular hypertrophy, electrolyte shifts, inflammation, and divalent ion abnormalities predispose patients to arrhythmias and sudden cardiac death. The risks are further increased by comorbidities like ischemic heart disease, prolonged QT interval, iron overload, and sympathetic overactivity. Preventive strategies include optimizing volume control with frequent or nocturnal dialysis, treating hypertension and left ventricular hypertrophy with beta blockers or calcium channel blockers, and managing inflammation and mineral bone disorders.
A simple description of a less understood topic in Intensive Care Medicine. Aim to make understanding and management easy for the residents and prevention steps for all ICU workers.
Dosage regimen in renal failure ( Neha Mayekar).pptxSaishDalvi
This document discusses dosage adjustment in patients with renal failure. It notes that renal failure can impact drug absorption, distribution, metabolism and excretion. Two main methods are described for adjusting dosages - based on drug clearance or based on changes in elimination rate constant. The goal is to maintain therapeutic drug concentrations while accounting for changes like prolonged half-life. Formulas for estimating creatinine clearance, which indicates renal function, are also provided to help determine appropriate dosage adjustments for patients with impaired kidney function.
This document provides guidelines for screening, treating, and managing lupus nephritis (LN). It defines LN and its classification system. For classes I and II LN, treatment focuses on extrarenal symptoms. Classes III and IV are treated aggressively with glucocorticoids and immunosuppressants. Maintenance therapy includes azathioprine or mycophenolate mofetil with low-dose steroids. Relapse is treated with the initial regimen. The guidelines recommend treatments and monitoring for various LN classes and complications.
Dose Adjustment in renal and hepatic failurePallavi Kurra
This document discusses dosage adjustments for patients with renal or hepatic failure. It covers:
1) Causes, classification, and measurement of renal failure including glomerular filtration rate (GFR) and creatinine clearance. Dosage adjustments are recommended based on GFR for various drug classes.
2) Causes, classification, and liver function tests for hepatic failure. Considerations for dosage adjustments in patients with hepatic impairment include drug elimination pathways and protein binding.
3) Formulas for estimating creatinine clearance from serum creatinine levels, including the Cockcroft-Gault and modification of diet in renal disease (MDRD) methods.
This document provides guidance statements on the diagnosis, evaluation and management of ascites, spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome (HRS) for patients with cirrhosis. It recommends moderate sodium restriction and diuretic therapy as first-line treatment for ascites. Large volume paracentesis is recommended for severe ascites. Albumin infusion and antibiotics are recommended for SBP treatment and prophylaxis. Vasoconstrictor drugs in combination with albumin are the treatment of choice for HRS, with terlipressin as the preferred drug.
Luspatercept is a first-in-class erythroid maturation agent that targets TGF-β ligands to block aberrant Smad2/3 signaling and augment late-stage erythropoiesis. It is indicated for treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusions. The BELIEVE trial met its primary endpoint, showing luspatercept significantly reduced transfusion burden in patients with beta-thalassemia. Additional trials show luspatercept was effective in reducing transfusion requirements in lower-risk myelodysplastic syndromes with ring sideroblasts and was generally well-tolerated. Luspatercept has the potential to be
This document summarizes current treatment guidelines for lupus nephritis. It defines lupus nephritis based on ACR criteria and recommends an early renal biopsy. For initial treatment of proliferative lupus nephritis (classes III/IV), guidelines differ on whether cyclophosphamide or mycophenolate mofetil is preferred. Maintenance therapy with mycophenolate mofetil or azathioprine with low-dose steroids is recommended, with mycophenolate mofetil showing better outcomes. Immunosuppression should be continued for at least one year after complete remission is achieved.
1) The ATTIRE trial investigated whether daily albumin infusions would reduce infections and organ dysfunction in hospitalized patients with cirrhosis compared to standard care. 2) Over 700 patients with cirrhosis were randomly assigned to either daily albumin infusions or standard care without explicit albumin therapy for up to 14 days. 3) The trial found no benefit of albumin therapy over standard care on the composite primary outcome of infections, organ dysfunction and mortality.
Venous thromboembolisms often result from Virchow's triad of altered blood flow, endothelial injury, and hypercoagulability. Lovenox is commonly used to treat and prevent VTEs as it inhibits coagulation factors Xa and IIa. It has high bioavailability, is metabolized in the liver, and has a half-life of 4.5-7 hours. Bleeding is the most common side effect. A multidisciplinary approach including hematology consultation is recommended for oncology patients at high risk of VTEs, as Lovenox is more effective than warfarin for this population.
Cirrhosis is irreversible scarring of the liver caused by various chronic liver injuries and diseases. It is a major global health issue and the 13th leading cause of death worldwide. The major causes of cirrhosis are hepatitis B, hepatitis C, alcoholism, and non-alcoholic fatty liver disease. Patients with cirrhosis have progressive liver damage and fibrosis that leads to complications including portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and liver cancer. Without treatment, survival is typically 10-13 years after diagnosis but can decrease to just 2 years once complications develop.
Optimization of Heart Failure Treatment ppt.pptxpradeepbansal34
The document discusses guidelines for treating heart failure with reduced ejection fraction (HFrEF). It recommends initiating all four foundational therapies - ACE inhibitors, ARBs, beta blockers, and mineralocorticoid receptor antagonists (MRA) - as early as possible without delay to maximize mortality benefits. The practical approach involves optimizing volume status with diuretics before starting renin-angiotensin system inhibitors (RASi). RASi are then up-titrated gradually followed by beta blockers and MRAs. Close monitoring is needed when using combinations of drugs to safely reach guideline directed medical therapy goals.
Discussion of the current medications of chronic hepatitis treatment in the Egyptian market as well as our protocol of management in the Viral Hepatitis Treatment Centers in Egypt. Discussion of the latest recommendations of AASLD/IDSA and EASL are presented
The document summarizes several drug approvals and updates from the FDA in August 2017. Mavyret was approved for treating HCV genotypes 1-6 without cirrhosis or with compensated cirrhosis. Carospir received approval as an oral suspension for heart failure, hypertension, and hepatic edema. Duzallo was approved as a combination of lesinurad and allopurinol for treating gout in patients not at target uric acid levels on allopurinol alone. Vabomere was approved for complicated UTIs caused by designated bacteria. Other notable approvals included Idhifa for AML, Besponsa for ALL, and Benznidazole for Chagas disease in pediatric patients.
This particular presentation of mine covers salient features of recent drug developed for treatment of dyslipidaemia particularly familial hypercholesterolemia. This presentation also covers recent modifications in treatment guidelines.
This document outlines the design of a randomized controlled trial testing the effects of empagliflozin versus placebo in patients with heart failure with preserved ejection fraction. Over 5,900 patients were enrolled and followed for a median of 26 months. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. Empagliflozin reduced the primary outcome compared to placebo and was generally well tolerated aside from higher rates of genital infections.
This document provides guidelines for perioperative care in elective colorectal surgery as part of an Enhanced Recovery After Surgery (ERAS) protocol. It makes recommendations for several preadmission items including preadmission counselling and education, preoperative optimization of medical conditions, prehabilitation, preoperative nutrition, management of anemia, and prevention of postoperative nausea and vomiting. The recommendations are based on reviews of the available evidence and are intended to reduce complications and facilitate early recovery after colorectal surgery.
This document provides an overview of anticoagulants including their mechanisms of action, indications, dosing, and monitoring. It discusses normal hemostasis and coagulation factors. Unfractionated heparin, low molecular weight heparins, and factor Xa inhibitors are described as parenteral anticoagulants. Oral anticoagulants reviewed include warfarin, rivaroxaban, apixaban, and dabigatran. The roles of clinical pharmacists in managing anticoagulation therapy are also mentioned.
This document discusses several deep fungal infections caused by dimorphic fungi, including blastomycosis, paracoccidioidomycosis, coccidioidomycosis, and histoplasmosis. It provides details on the causative agents, modes of transmission, clinical presentations, laboratory diagnosis including microscopy and culture, and treatment for each infection. The infections are acquired through inhalation of fungal spores from the soil and can affect the lungs, skin, and other organs. Laboratory diagnosis involves microscopy of specimens to identify fungal structures, culture, and serological tests. Antifungals such as amphotericin B and azoles are used as treatment.
Sudden Cardiac Death and Chronic Kidney DiseaseShodhan Patel
Sudden cardiac death is responsible for about one fourth of all cause mortality in dialysis patients. In chronic kidney disease, factors like left ventricular hypertrophy, electrolyte shifts, inflammation, and divalent ion abnormalities predispose patients to arrhythmias and sudden cardiac death. The risks are further increased by comorbidities like ischemic heart disease, prolonged QT interval, iron overload, and sympathetic overactivity. Preventive strategies include optimizing volume control with frequent or nocturnal dialysis, treating hypertension and left ventricular hypertrophy with beta blockers or calcium channel blockers, and managing inflammation and mineral bone disorders.
Prevention in Cardiology Myths or RealityShodhan Patel
Dr. Shodhan Patel presented on myths and realities related to prevention of coronary heart disease. Some myths discussed included that CAD only affects wealthy countries, elderly males, and that cholesterol-lowering drugs allow an unhealthy diet. Realities included CAD being common in poor populations, younger adults and females, the harms of trans fats and benefits of exercise. Stress and an unhealthy lifestyle from a young age can increase risk factors for heart disease. Public press can help spread scientific information to help more people make beneficial lifestyle changes for prevention.
This document discusses hypertension (high blood pressure). It defines hypertension and lists risk factors such as obesity, sodium intake, stress, and lack of physical activity. It describes mechanisms of hypertension including increased intravascular volume, the renin-angiotensin system, the sympathetic nervous system, vascular changes, and immune/inflammatory factors. Secondary causes of hypertension like kidney disease and primary aldosteronism are explained. Treatment involves lifestyle modifications and drug therapy. Blood pressure goals of therapy and the distinction between hypertensive emergencies and urgencies are also summarized.
Domestic Violence during antenatal periodShodhan Patel
This document discusses domestic violence during pregnancy and its effects. It notes that 1 in 5 mothers experience abuse during pregnancy. Domestic violence can harm the physical and mental health of the mother and increase risks for low birth weight, preterm birth, and perinatal mortality in the baby. Factors like young age, poverty, and unwanted pregnancy can increase the risks of domestic violence during pregnancy. The document also discusses the importance of preconception care and antenatal care in improving maternal and child health outcomes.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
2. PES Institute of Medical Sciences & Research
• Brand name: Jakavi
• Class: Protein kinase inhibitors
3. PES Institute of Medical Sciences & Research
DESCRIPTION AND COMPOSITION
Pharmaceutical form:
• 5mg tablets
• 10mg tablets
• 15mg tablets
• 20mg tablets
4. PES Institute of Medical Sciences & Research
Active substance
• Ruxolitinib phosphate
• Ruxolitinib 5 mg per tablet
• Ruxolitinib 10 mg per tablet
• Ruxolitinib 15 mg per tablet
• Ruxolitinib 20 mg per tablet.
Active Moiety
• Ruxolitinib
5. PES Institute of Medical Sciences & Research
Excipients
Cellulose, microcrystalline; Lactose monohydrate; Magnesium stearate;
Silica, colloidal anhydrous; Sodium starch glycolate (Type A);
Hydroxypropylcellulose; Povidone
• Each 5 mg tablet contains 71.45 mg of lactose monohydrate
• Each 10 mg tablet contains 142.90 mg of lactose monohydrate
• Each 15 mg tablet contains 214.35 mg of lactose monohydrate
• Each 20 mg tablet contains 285.80 mg of lactose monohydrate.
6. PES Institute of Medical Sciences & Research
INDICATIONS
• Myelofibrosis
Jakavi is indicated for the treatment of disease-related splenomegaly
and/or symptoms in adult patients with myelofibrosis, including primary
myelofibrosis, post-polycythemia vera myelofibrosis or post-essential
thrombocythemia myelofibrosis.
• Polycythemia vera
Jakavi is indicated for the treatment of adult patients with polycythemia
vera who are resistant to or intolerant of hydroxyurea
7. PES Institute of Medical Sciences & Research
DOSAGE REGIMEN AND ADMINISTRATION
• Monitoring instructions
Blood cell counts: a blood cell count must be performed before
initiating therapy with Jakavi.
Complete blood counts should be monitored every 2 to 4 weeks
until doses are stabilized, and then as clinically indicated.
8. PES Institute of Medical Sciences & Research
Starting dose
• The recommended starting dose of Jakavi in myelofibrosis (MF) is based
on platelet counts
• Starting Doses in Myelofibrosis
Platelet count Starting dose
Greater than 200,000/mm3 20 mg orally twice daily
100,000 to 200,000/mm3 15 mg orally twice daily
75,000 to less than 100,000/mm3 10 mg orally twice daily
50,000 to less than 75,000/mm3 5 mg orally twice daily
9. PES Institute of Medical Sciences & Research
Dose modifications
• The recommended starting dose of Jakavi in Polycythemia vera (PV) is
10 mg given orally twice daily.
• Doses may be titrated based on efficacy and safety
• If efficacy is considered insufficient and blood counts are adequate,
doses may be increased by a maximum of 5 mg twice daily, up to the
maximum dose of 25 mg twice daily.
• The starting dose should not be increased within the first four weeks of
treatment and thereafter no more frequently than at 2-week intervals.
10. PES Institute of Medical Sciences & Research
Contd...
• Treatment should be interrupted for platelet counts less than
50,000/mm3 or absolute neutrophil counts less than 500/mm3
• In PV, treatment should also be interrupted when hemoglobin is below 8
g/dL.
• After recovery of blood counts above these levels, dosing may be
restarted at 5 mg twice daily and gradually increased based on careful
monitoring of blood cell counts.
• Dose reductions should be considered if the platelet counts decrease
during treatment with the goal of avoiding dose interruptions for
thrombocytopenia.
11. PES Institute of Medical Sciences & Research
Dosing Recommendation for Thrombocytopenia
Dose at time of Platelet Decline
25 mg
twice daily
20 mg
twice daily
15 mg
twice daily
10 mg
twice daily
5 mg
twice daily
Platelet count New Dose
100,000 to
<125,000/mm3
20 mg
twice daily
15 mg
twice daily
No change No change No change
75,000 to
<100,000/mm3
10 mg
twice daily
10 mg
twice daily
10 mg
twice daily
No change No change
50,000 to <75,000/mm3 5 mg
twice daily
5 mg
twice daily
5 mg
twice daily
5 mg
twice daily
No change
Less than 50,000/mm3 Hold Hold Hold Hold Hold
12. PES Institute of Medical Sciences & Research
Contd...
• In PV, dose reduction should also be considered if hemoglobin
decreases below 12 g/dL and is recommended if hemoglobin decreases
below 10 g/dL
• Administration instruction:
• If a dose is missed, the patient should not take an additional dose, but should take
the next usual prescribed dose.
• Treatment may be continued as long as the benefit: risk ratio remains positive.
13. PES Institute of Medical Sciences & Research
Dose adjustment with concomitant strong
CYP3A4 Inhibitors or fluconazole:
• When Jakavi is administered with strong CYP3A4 inhibitors or dual
moderate inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole),
the unit dose of Jakavi should be reduced by approximately 50%, to be
administered twice daily. The concomitant use of Jakavi with fluconazole
doses greater than 200 mg daily should be avoided.
• More frequent monitoring of hematology parameters and clinical signs
and symptoms of Jakavi related adverse drug reactions (ADRs) is
recommended while on a strong CYP3A4 inhibitor or dual moderate
inhibitors of CYP2C9 and CYP3A4 enzymes.
14. PES Institute of Medical Sciences & Research
Special populations
• Renal impairment
• In patients with severe renal impairment (creatinine clearance (Clcr) less than
30mL/min) the recommended starting dose based on platelet count for MF
patients should be reduced by approximately 50%. The recommended starting
dose for PV patients with severe renal impairment is 5 mg twice daily. Patients
diagnosed with severe renal impairment while receiving Jakavi should be carefully
monitored and may need to have their doses reduced to avoid ADRs.
15. PES Institute of Medical Sciences & Research
Contd...
• There are limited data to determine the best dosing options for patients with end-
stage renal disease (ESRD) on dialysis. Available data in this population suggest that
MF patients on dialysis should be started on an initial single dose of 15 mg or 20 mg
based on platelet counts with subsequent single doses only after each dialysis
session, and with careful monitoring of safety and efficacy. The recommended
starting dose for PV patients with ESRD on hemodialysis is a single dose of 10 mg or
two doses of 5 mg given 12 hours apart, to be administered post-dialysis and only on
the day of haemodialysis. These dose recommendations are based on simulations
and any dose modification in ESRD should be followed by careful monitoring of
safety and efficacy in individual patients. No data is available for dosing patients who
are undergoing peritoneal dialysis or continuous venovenous haemofiltration
16. PES Institute of Medical Sciences & Research
Hepatic Impairment
• In patients with any hepatic impairment the recommended starting dose based on
platelet count should be reduced by approximately 50% to be administered twice
daily. Subsequent doses should be adjusted based on careful monitoring of safety
and efficacy. Patients diagnosed with hepatic impairment while receiving Jakavi
should have complete blood counts, including a white blood cell count differential,
monitored at least every one to two weeks for the first 6 weeks after initiation of
therapy with Jakavi and as clinically indicated thereafter once their liver function and
blood counts have been stabilised. Jakavi dose can be titrated to reduce the risk of
cytopenia.
17. PES Institute of Medical Sciences & Research
Contd...
• Pediatrics
• Safety and efficacy of Jakavi in pediatric patients have not been established.
• Geriatrics
• No additional dose adjustments are recommended for elderly patients
18. PES Institute of Medical Sciences & Research
Method of administration
• Jakavi is dosed orally and can be administered with or without
food.
• CONTRAINDICATIONS:
• Hypersensitivity to the active substance or any of the excipients.
19. PES Institute of Medical Sciences & Research
WARNINGS AND PRECAUTIONS
• Decrease in blood cell count
• Treatment with Jakavi can cause hematological ADRs, including
thrombocytopenia, anemia and neutropenia. A complete blood count must be
performed before initiating therapy with Jakavi
• It has been observed that patients with low platelet counts (<200,000/mm3) at the
start of therapy are more likely to develop thrombocytopenia during treatment.
• Thrombocytopenia was generally reversible and was usually managed by
reducing the dose or temporarily withholding Jakavi. However, platelet
transfusions may be required as clinically indicated
20. PES Institute of Medical Sciences & Research
Contd...
• Patients developing anemia may require blood transfusions. Dose
modifications or interruption for patients developing anemia may also
be considered.
• Neutropenia (Absolute Neutrophil Count (ANC) <500/mm3) was
generally reversible and was managed by temporarily withholding
Jakavi
• Complete blood counts should be monitored as clinically indicated and
dose adjusted as required
21. PES Institute of Medical Sciences & Research
Infections
• Serious bacterial, mycobacterial, fungal, viral and other opportunistic
infections have occurred in patients treated with Jakavi. Patients should
be assessed for the risk of developing serious infections. Physicians
should carefully observe patients receiving Jakavi for signs and
symptoms of infections and appropriate treatment should be initiated
promptly. Jakavi therapy should not be started until active serious
infections have resolved.
22. PES Institute of Medical Sciences & Research
Contd...
• Tuberculosis has been reported in patients receiving Jakavi. Before
starting treatment, patients should be evaluated for active and inactive
(“latent”) tuberculosis, as per local recommendations.
• Hepatitis B viral load (HBV-DNA titre) increases, with and without
associated elevations in alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), have been reported in patients with chronic
HBV infections taking Jakavi. The effect of Jakavi on viral replication in
patients with chronic HBV infection is unknown. Patients with chronic
HBV infection should be treated and monitored according to clinical
guidelines.
23. PES Institute of Medical Sciences & Research
Herpes zoster
• Physicians should educate patients about early signs and symptoms of
herpes zoster, advising that treatment should be sought as early as
possible.
• Progressive multifocal leukoencephalopathy:
• Progressive Multifocal leukoencephalopathy (PML) has been reported with Jakavi
treatment. Physicians should be alert for neuropsychiatric symptoms suggestive
of PML. If PML is suspected, further dosing must be suspended until PML has
been excluded.
24. PES Institute of Medical Sciences & Research
Non-melanoma skin cancer
• Non-melanoma skin cancers (NMSCs), including basal cell, squamous
cell, and Merkel cell carcinoma, have been reported in patients treated
with Jakavi. Most of these patients had histories of extended treatment
with hydroxyurea and prior NMSC or pre-malignant skin lesions. A causal
relationship to Jakavi has not been established. Periodic skin xamination
is recommended for patients who are at increased risk for skin cancer.
25. PES Institute of Medical Sciences & Research
Lipid abnormalities/elevations
• Treatment with Jakavi has been associated with increases in lipid
parameters including total cholesterol, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.
Lipid monitoring and treatment of dyslipidemia according to clinical
guidelines is recommended.
26. PES Institute of Medical Sciences & Research
Special populations
• Renal impairment
• The starting dose of Jakavi should be reduced in patients with severe renal
impairment. For patients with ESRD on dialysis the starting dose should be based
on platelet counts for MF patient, while the recommended starting dose is a single
dose of 10 mg for PV patients. Subsequent doses for both MF and PV patients
should be administered only on hemodialysis days following each dialysis
session. Further dose modifications should be based on the safety and efficacy of
the drug
27. PES Institute of Medical Sciences & Research
Hepatic impairment
• The starting dose of Jakavi should be reduced in patients with hepatic
impairment. Further dose modifications should be based on the safety
and efficacy of the drug
28. PES Institute of Medical Sciences & Research
Interactions
• If Jakavi is to be co-administered with strong CYP3A4 inhibitors or dual
moderate inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole),
the unit dose of Jakavi should be reduced by approximately 50%, to be
administered twice daily
29. PES Institute of Medical Sciences & Research
Withdrawal effects
• Following interruption or discontinuation of Jakavi, symptoms of
myelofibrosis may return over a period of approximately one week. There
have been cases of patients discontinuing Jakavi who sustained more
severe events, particularly in the presence of acute intercurrent illness. It
has not been established whether abrupt discontinuation of Jakavi
contributed to these events. Unless abrupt discontinuation is required,
gradual tapering of the dose of Jakavi may be considered, although the
utility of the tapering is unproven.
30. PES Institute of Medical Sciences & Research
ADVERSE DRUG REACTIONS
ADRs Frequency category
for MF patients
Frequency category
for PV patients
Infections and infestations
Urinary tract infections Very common Very common
Herpes zoster Very common Very common
Pneumonia Very common Common
Blood and lymphatic system disorders
Bruising Very common Very common
Anaemia Very common Very common
Thrombocytopenia Very common Very common
Neutropenia Very common common
Bleeding (any bleeding including intracranial, and
gastrointestinal bleeding, bruising and other
bleeding
Very common Very common
Gastrointestinal bleeding Very Common Common
31. PES Institute of Medical Sciences & Research
Contd...
ADRs Frequency category
for MF patients
Frequency category
for PV patients
Metabolism and nutrition disorders Very common Very common
Hypercholesterolaemia Very common Very common
Hypertriglyceridaemia Very common Very common
Weight gain Very common Very common
Nervous system disorders Very common Very common
Dizziness Very common Very common
Headache Very common Very common
Gastrointestinal disorders Very common Very common
Constipation Very common Very common
32. PES Institute of Medical Sciences & Research
Contd...
ADRs Frequency category
for MF patients
Frequency category
for PV patients
Hepatobiliary disorders Very common Very common
Raised ALT Very common Very common
Raised AST Very common Very common
Vascular disorders Very common Very common
Hypertension Very common Very common
Upon discontinuation, MF patients may experience a return of MF symptoms such as fatigue,
bone pain, fever, pruritus, night sweats, symptomatic splenomegaly and weight loss. In MF
clinical studies the total symptom score for MF symptoms gradually returned to baseline value
within 7 days after dose discontinuation
33. PES Institute of Medical Sciences & Research
PREGNANCY & LACTATION
• The use of Jakavi during pregnancy is not recommended. The patient
should be advised of the risk to a fetus if Jakavi is used during pregnancy
or if the patient becomes pregnant while taking this medicinal product.
34. PES Institute of Medical Sciences & Research
OVERDOSAGE
• There is no known antidote for overdoses with Jakavi. Single doses up to
200 mg have been given with acceptable acute tolerability. Higher than
recommended repeat doses are associated with increased
myelosuppression including leukopenia, anemia and thrombocytopenia.
Appropriate supportive treatment should be given.
• Hemodialysis is not expected to enhance the elimination of ruxolitinib.
35. PES Institute of Medical Sciences & Research
CLINICAL PHARMACOLOGY
• Pharmacotherapeutic group, ATC
• ATC code L01EJ01 (protein kinase inhibitors)
• Mechanism of action (MOA)
• Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1
and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes,
respectively). These mediate the signaling of a number of cytokines and growth
factors that are important for hematopoiesis and immune function. JAK signaling
involves recruitment of signal transducers and activators of transcription (STATs)
to cytokine receptors, activation, and subsequent localization of STATs to the
nucleus leading to modulation of gene expression. Dysregulation of the JAK-
STAT pathway has been associated with several cancers and increased
proliferation and survival of malignant cells.
36. PES Institute of Medical Sciences & Research
Contd...
• MF and PV are myeloproliferative neoplasms (MPN) known to be
associated with dysregulated JAK1 and JAK2 signaling. The basis for the
dysregulation is believed to include high levels of circulating cytokines
that activate the JAK-STAT pathway, gain-of function mutations such as
JAK2V617F, and silencing of negative regulatory mechanisms. MF
patients exhibit dysregulated JAK signaling regardless of JAK2V617F
mutation status. Activating mutations in JAK2 (V617F or exon 12) are
found in >95% of PV patients.
37. PES Institute of Medical Sciences & Research
Pharmacodynamics (PD)
• Ruxolitinib inhibits cytokine induced STAT3 phosphorylation in whole
blood from healthy subjects and MF and PV patients. Ruxolitinib resulted
in maximal inhibition of STAT3 phosphorylation 2 hours after dosing
which returned to near baseline by 8 hours in both healthy subjects and
MF patients, indicating no accumulation of either parent or active
metabolites.
38. PES Institute of Medical Sciences & Research
Pharmacokinetics (PK)
• Absorption
• Ruxolitinib is a Class 1 molecule under the Biopharmaceutical Classification
System, with high permeability, high solubility and rapid dissolution
characteristics. In clinical studies, ruxolitinib is rapidly absorbed after oral
administration with maximal plasma concentration (Cmax) achieved
approximately 1 hour post-dose. Based on a mass balance study in humans, oral
absorption of ruxolitinib was 95% or greater. Mean ruxolitinib Cmax and total
exposure (AUC) increased proportionally over a single dose range of 5 to 200 mg
39. PES Institute of Medical Sciences & Research
Distribution
• The mean volume of distribution at steady-state is 72 L in MF patients
with an inter-subject variability of 29.4% and 75 L in PV patients with an
associated inter-subject variability of 22.6%. At clinically relevant
concentrations of ruxolitinib, binding to plasma proteins in vitro is
approximately 97%, mostly to albumin. A whole body autoradiography
study in rats has shown that ruxolitinib does not penetrate the blood-
brain barrier.
40. PES Institute of Medical Sciences & Research
Biotransformation/metabolism
• In vitro studies indicate that CYP3A4 and CYP2C9 are the major enzyme
responsible for metabolism of ruxolitinib
• At clinically relevant concentrations, ruxolitinib does not inhibit CYP1A2,
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 and is not
a potent inducer of CYP1A2, CYP2B6 or CYP3A4 based on in vitro
studies.
41. PES Institute of Medical Sciences & Research
Elimination
• Following a single oral dose, 74% of radioactivity excreted in urine and
22% excretion via feces. Unchanged drug accounted for less than 1% of
the excreted total radioactivity.
• The mean elimination half-life of ruxolitinib is approximately 3 hours.
42. PES Institute of Medical Sciences & Research
Reference:
• Novartis Pharma AG, Basel, Switzerland Study and Research
Article